Benitec Biopharma Inc. (BNTC) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0125K250K375K500K625K750K875K1MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0815223038455260Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesGeneral And Administrative ExpensesOther Expenses
04M8M11M15M19M22M26M30MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
-30M-26M-22M-19M-15M-11M-7M-4M1Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income Variation
01020304050607080Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
-200-175-150-125-100-74-49-241Q3 2025

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY Variation
01K2K4K5K6K8K9K10KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
-20-17-15-12-10-7-4-21Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
0375K750K1M2M2M2M3M3MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
0510152025303540Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
💰 Cash Flow Statement

Operating Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
02K5K8K10K12K15K18K20KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Cash At End Of Period
025M50M75M100M125M150M175M200MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
05M10M15M20M25M30M35M40MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
🏦 Balance Sheet
📈 Key Metrics